(3-氯苯基)[3,4-二氢-6,7-二甲氧基-1-[[(4-甲氧基苯氧基)甲基]-2(1H)-异喹啉基]甲酮 | 486427-17-2

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: (3-氯苯基)[3,4-二氢-6,7-二甲氧基-1-[[(4-甲氧基苯氧基)甲基]-2(1H)-异喹啉基]甲酮
• 中文别名: (3-氯苯基)[3,4-二氢-6,7-二甲氧基-1-[(4-甲氧基苯氧基)甲基]-2(1H)-异喹啉基]甲酮
• 英文名称: (3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
• 英文别名: (3-chlorophenyl)-[6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]methanone
• CAS: 486427-17-2
• 化学式: C₂₆H₂₆ClNO₅
• 分子量: 467.9
• InChiKey: VYMILMYEENZHAR-UHFFFAOYSA-N

物化性质

• 沸点：
  635.8±55.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO：加热至60℃时≥10mg/mL

制备方法与用途

生物活性

CIQ是一种亚基选择性的NMDA受体增强剂, 作用于NR2C或NR2D亚基。

文献信息

• [EN] GLUN2C/D SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTOR<br/>[FR] ANTAGONISTES SÉLECTIFS DES SOUS-UNITÉS GLUN2C/D DU RÉCEPTEUR N-MÉTHYL-D-ASPARTATE
  申请人：UNIV EMORY

  公开号：WO2019191424A1

  公开（公告）日：2019-10-03

  A compound according to Formula (I) or salts or prodrugs thereof and pharmaceutical formulations comprising the compound are provided herein for the treatment of neurological disorders. The disorders may include providing neuroprotection, preventing neurodegeneration, treating neuropathic pain or treating schizophrenia, psychoses or depression. Furthermore, the compounds may be used in combination with another active ingredient.

  根据公式（I）提供的化合物或其盐或前药，以及包含该化合物的药物配方，用于治疗神经系统疾病。这些疾病可能包括提供神经保护、预防神经退化、治疗神经病性疼痛或治疗精神分裂症、精神病或抑郁症。此外，这些化合物可以与另一种活性成分结合使用。
• Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
  申请人：EMORY UNIVERSITY

  公开号：US10273214B2

  公开（公告）日：2019-04-30

  Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.

  本发明提供了治疗或预防与 NMDA 受体活性相关的疾病的化合物、药物组合物和方法，这些疾病包括精神分裂症、帕金森病、认知障碍、抑郁症、神经性疼痛、中风、脑外伤、癫痫以及相关的神经系统事件或神经变性。本文公开了通式 A-J 的化合物及其药学上可接受的盐、酯、原药或衍生物。
• Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions
  申请人：Traynelis Stephen F.

  公开号：US20120028977A1

  公开（公告）日：2012-02-02

  Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.
• US20140275529A1
  申请人：——

  公开号：US20140275529A1

  公开（公告）日：2014-09-18
• NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Sage Therapeutics, Inc.

  公开号：US20170304321A1

  公开（公告）日：2017-10-26

  Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modulating compound, are provided.